Amoéba

Regulatory Filings • Mar 13, 2023

Press release

AMOEBA announces initiation report from the analyst Edison Group

Lyon (France), March 13th, 2023 – 17:45 – AMOÉBA (FR0011051598 – ALMIB), an industrial biotech in pre-commercialization* specializing in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces that Edison Group, a London-based equity research house, has initiated coverage on the company.

This research contract, financed by the company, aims to allow investors to broaden their understanding of the company, which is necessary to take a position on Amoéba shares (ALMIB).

The first note, entitled "Amoéba, fighting pathogens, respecting nature" is available to all investors and provides insight into the business' plans to raise €45m to fund its operations and expand its site over the next three years. Subsequent research will keep shareholders up to date with Amoeba's finances, strategy and operational progress.

The company informs that, as Amoéba plans to double the size of its biocontrol plant in Cavaillon in 2027, Edison Group's estimations on this first note are based on a production capacity allowing the treatment of 200 000 hectares.

Edison's research is available on Amoéba's website in the "Shareholding / Coverage" section as well as directly from the Edison website and via major financial data providers including Bloomberg.

About AMOÉBA :

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba Willaertia magna C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €1.6 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (4) in the United States. The commercialization of the associated healthcare, biocides and phytosanitary products is subject to local regulatory approvals. *At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a precommercialization phase for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010 and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

(1): Amoéba data

(2): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

(3): Amoeba data

(4): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts :

Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com

Calyptus

Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of AMOEBA to be materially different from such forwardlooking statements.